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a  b  s  t  r  a  c  t
A  new  glycerol-based  trifunctional  block  copolymer  (TBC)  of propylene  oxide  and  ethylene  oxide  and
its  conjugate  with  succinic  acid  (TBC–SA)  were  studied  as  a drug  delivery  system  and  compared  with
Pluronic  L61.  TBCs  have  multiple  effects  on  the  plasma  membrane  of human  cells,  e.g.  increasing  its
ﬂuidity  and  ion  permeability,  inhibiting  ATPase  activity  of efﬂux  transporter  P-glycoprotein  through
reversible  membrane  destabilization.  Such  membrane-modulating  properties  attributed  to  the unimer
form  of  copolymers  increase  in  the  order  Pluronic  L61   TBC < TBC–SA  and  correlate  with  an  ability  of
TBCs  to promote  the  accumulation  of  P-glycoprotein  substrates  in  lung cancer  A549 cells.  Furthermore,
TBC,  and  especially  TBC–SA,  exhibit  substantially  lower  hemolytic,  cytotoxic  and  proapoptotic  activities
in  comparison  with  Pluronic  L61.  Our results  demonstrate  that  TBCs  are  promising  analogs  of  bifunctional
Pluronics  in  anticancer  drug  delivery.
© 2013 Elsevier B.V. All rights reserved.
1. Introduction
Nonionogenic amphiphilic polymers have a variety of appli-
cations in petroleum production, chemical technologies and are
also an important component of household products. Depending
on their physicochemical properties, e.g. the hydrophilic–lipophilic
balance (HLB), such polymers exhibit different effects on living cells
as a result of a reversible interaction with amphiphilic cellular com-
ponents, especially lipid membranes and membrane-associated
proteins (Firestone and Seifert, 2005; Batrakova and Kabanov,
2008; Alakhova et al., 2010). The biological properties of these
amphiphilic polymers are of particular interest with regard to their
potential (cyto-)toxicity, as well as an intriguing possibility of their
therapeutic application.
Bifunctional block copolymers of ethylene oxide and propyl-
ene oxide (PluronicsTM) have been systematically studied as drug
carriers (Venne et al., 1996; Kabanov et al., 2002; Batrakova and
Kabanov, 2008; Valle et al., 2011; Wei  et al., 2013). Pluronic-based
micellar formulations allow for the encapsulation of hydrophobic
drugs, improving their solubility and increasing blood circulation
time (Wang et al., 2007; Yoncheva et al., 2012). Other applications
of Pluronics include the development of: hydrogels for topical drug
delivery (Jansen et al., 2013), immuno-adjuvants (Newman et al.,
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1998) and cellular membrane protectors (Serbest et al., 2006; Mina
et al., 2009).
Although in above applications Pluronics have been exploited
as relatively inert surfactants, a series of recent studies show that
Pluronics may  directionally affect some cellular functions includ-
ing: gene expression (Batrakova and Kabanov, 2008), energetic
metabolism (Alakhova et al., 2010) and membrane transporter
activity (Wei  et al., 2013). These effects are more pronounced in
Pluronics with low and intermediate HLB, such as Pluronics L61
and P85, which were found to promote drug transport across the
blood brain barrier as well as into multidrug resistant cancer cells,
making them more sensitive to conventional chemotherapy (Venne
et al., 1996; Batrakova and Kabanov, 2008). To date, several com-
positions of existing anticancer drugs and Pluronics L61/F127 have
been developed by Supratek Pharma Inc. to treat solid tumors and
leukemia. One formulation SP1049C containing the anthracycline
antibiotic doxorubicin is in phase III of clinical trials (Valle et al.,
2011).
The principal limitation of hydrophobic Pluronics (e.g. Pluronic
L61) as candidates for drug delivery is high cytotoxic/proapoptotic
action which restricts their pharmaceutical application. Safer
amphiphilic polymers with balanced speciﬁc and cytotoxic activ-
ities are ones of choice in advanced polymer-based therapy. A
promising strategy is the development of polyfunctional analogs
of Pluronics on the basis of biochemical structures. Recently, we
have demonstrated that the conjugation of hydrophobic Pluron-
ics with succinic acid modulates their interaction with the plasma
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